Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Other: Placebo Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle?

NCT00730184
View directory record Official record
Conditions
Osteoporosis, Sarcopenia
Interventions
potassium bicarbonate, Placebo (microcrystalline cellulose)
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Formulation A, AGN-199201 Formulation B, AGN-199201 Formulation C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

NCT05997277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of OPC Factor on Energy Levels

NCT00318019
View directory record Official record
Conditions
Healthy
Interventions
OPC Factor(TM), Placebo
Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

NCT01773707
View directory record Official record
Conditions
Abnormal Glucose Tolerance, Type 1 Diabetes
Interventions
CTLA4-Ig (Abatacept), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

NCT05095311
View directory record Official record
Conditions
Exercise-induced Arterial Hypoxemia
Interventions
Cetirizine HCl, Placebo
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 2, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Carotenoid Supplementation and Retinal Health in Healthy Adults

NCT07314411
View directory record Official record
Conditions
Healthy
Interventions
other, Placebo
Dietary Supplement
Lead sponsor
Pacific University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Forest Grove, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

NCT04472598
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Placebo for Navitoclax, Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
35
States / cities
Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2Phase 3 Interventional

NRX101 Glx Biomarker Validation Study

NCT03402152
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
NRX-101, Lurasidone HCl, Placebo
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Casinomacropeptide and Satiety

NCT01587911
View directory record Official record
Conditions
Lack of Satiety, Excess Intake of Macronutrients, Appetite Disorders
Interventions
Whey, Whey-CMP, Control, CMP, MPI, CPI
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 2, 2026, 9:14 AM EDT
Active, not recruiting Not applicable Interventional

Chicago Social Drinking Project

NCT00961792
View directory record Official record
Conditions
Alcoholism
Interventions
Ethanol, Placebo, Diphenhydramine, Caffeine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

NCT00158600
View directory record Official record
Conditions
Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2
Interventions
alglucosidase alfa, Placebo
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
8 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04988308
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab, Adalimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Is Topical CBD Effective in Treating Thumb Joint Arthritis

NCT04611347
View directory record Official record
Conditions
CBD, Hand Osteoarthritis
Interventions
CBD, Shea Butter
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

NCT00521196
View directory record Official record
Conditions
Migraine
Interventions
DC Stimulator (Transcranial Direct Current Stimulator)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 2, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19

NCT06766279
View directory record Official record
Conditions
Anosmia
Interventions
Osteopathic Manipulative Treatment, Sham treatment
Procedure
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

NCT01720446
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
3,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
97
States / cities
Birmingham, Alabama • Chandler, Arizona • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

NCT05227703
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine 15 mg, Emraclidine 30 mg, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 2, 2026, 9:14 AM EDT